This article is more than 5 years old. Information may no longer be current.
Scott D. Solomon, MD: PARADIGM-HF results support new gold standard for HF therapy
BARCELONA, SPAIN — In this video, Scott D. Solomon, MD, professor of medicine at Harvard Medical School and director of noninvasive cardiology at Brigham and Women's Hospital, outlines results from the PARADIGM-HF study, presented during the ESC Congress.
Researchers assessed the use of LCZ696, an angiotensin receptor-neprilysin inhibitor, vs. enalapril, in addition to standard care, in a cohort of patients with NYHA class II, III or IV HF and ejection fraction of 40% or lower. During a median follow-up of 27 months, Solomon said researchers observed a significant 20% reduction in the composite primary endpoint of CV-related death and HF hospitalization, as well as a 16% reduction in all-cause mortality. He also noted that LCZ696 was better tolerated than enalapril.
He concluded that the results from PARADIGM-HF support replacing the gold standard of HF therapy with this new agent. He noted that a new trial will be conducted to assess the use of LCZ696 in patients with HF with preserved ejection fraction.